Oncobiologics plans to price IPO of 5,833,334 units at $6.00 per unit

Jefferies, Barclays are bookrunners; Cantor Fitzgerald is lead manager

By Devika Patel

Knoxville, Tenn., May 11 – Oncobiologics, Inc. will sell 5,833,334 units in its initial public offering with a 30-day greenshoe of 875,000 additional units, according to a Form S-1/A filed Wednesday with the Securities and Exchange Commission. The company has registered up to $90,897,928 of stock for the deal, which was announced as a stock offering on Jan. 15.

The units of one common share and two half-share warrants will be sold at an expected price of $6.00 per share. Each whole series A warrant is expected to be exercisable at $6.60 and each whole series B warrant is expected to be exercisable at $8.50.

Existing stockholder Sabby Healthcare Master Fund, Ltd. has indicated an interest in purchasing $5 million in units at the initial public offering price in a private placement that would settle concurrently with this offering.

Jefferies LLC and Barclays are the bookrunners. Cantor Fitzgerald & Co. is the lead manager.

Proceeds will be used for clinical trials, research, working capital and general corporate purposes.

The biopharmaceutical company is based in Cranbury, N.J. The company intends to list its common stock on the Nasdaq stock exchange under the symbol “ONS.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.